To include your compound in the COVID-19 Resource Center, submit it here.

Mepolizumab: Additional Phase III data

Additional data from the double-blind, international Phase III MEA115575 (SIRIUS) trial in 135 patients showed that patients receiving 100 mg subcutaneous mepolizumab given every 4 weeks for 20 weeks were 2.39 times more likely to achieve a

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers